Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2018

The following table summarizes stock option activities for the six months ended June 30, 2018:

	Stock Options		Weighted Average ‎ Exercise Price		Weighted Average ‎ Remaining ‎ Contractual Life (in ‎ years)
Nonvested at December 31, 2017		1,241,675	$	5.73		9.31
Options granted		-		-		-
Options outstanding		1,241,675		5.73		8.81
Options vested and exercisable at June 30, 2018		285,419	$	5.73		8.81

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2018 and 2017 (in thousands).

	For the three months ended June 30,					For the six months ended June 30,
	2018			2017		2018		2017
Employee	$	1,018		$	334	$	1,723	$	334
Non-employee		(47	)		63		1,243		63
Total stock-based compensation expense	$	971		$	397	$	2,966	$	397

A summary of warrant activities for six months ended June 30, 2018 is presented below:

	Warrants			Weighted Average ‎ Exercise Price		Weighted Average ‎ Remaining ‎ Contractual Life (in ‎ years)
Outstanding as of December 31, 2017		5,253,318		$	8.28		3.89
Granted		-			-		-
Exercised		(42,343	)		4.28		-
Outstanding as of June 30, 2018		5,210,975		$	8.32		3.60

The following table summarizes restricted stock award activities for the six months ended June 30, 2018:

	Number of Shares		Weighted Average ‎ Grant Date Fair ‎ Value
Nonvested at December 31, 2017		180,000	$	5.73
Granted		50,000		7.89
Nonvested at June 30, 2018		230,000	$	6.20

The following table summarizes restricted stock units activities for the six months ended June 30, 2018:

	Number of Units			Weighted Average ‎ Grant Date Fair ‎ Value
Nonvested at December 31, 2017		134,000		$	6.53
Granted		579,000			10.82
Vested		(100,000	)		10.29
Nonvested at June 30, 2018		613,000		$	9.97